ArticleFrontiers in immunology2025
Dynamics of HBsAb persistence and associated BCR IgG-H CDR3 repertoire features in ultra-high versus extremely low responders to HBV vaccination.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the duration of hepatitis B surface antibody (HBsAb) level maintenance and characterize the corresponding IgG-H CDR3 repertoire in volunteers exhibiting either ultra-high or extremely low HBsAb levels following hepatitis B virus (HBV) vaccination. Methods: This study was designed to monitor the longitudinal changes in HBsAb levels at multiple time points post-vaccination in healthy volunteers exhibiting either ultra-high or extremely low antibody responses following HBV vaccination. Furthermore, we employed high-throughput sequencing technology to conduct a comprehensive analysis of the compositional differences in the IgG-H CDR3 repertoire. Peripheral blood samples were collected at four distinct phases: pre-vaccination, post-second vaccination, post-third vaccination, and during the follow-up period, to characterize the dynamic changes in the antibody repertoire. Results: The longitudinal analysis revealed distinct patterns in antibody response kinetics between the two groups. In the ultra-high responder cohort, a peak HBsAb level (25,354 ± 17,993 mIU/mL) was observed following the second vaccine dose. This was followed by a gradual decline, with mean levels stabilizing at 11,356 ± 9,098 mIU/mL post-third dose and 4,229 ± 2,694 mIU/mL at the 4-year follow-up. The ultra-high hepatitis B surface antibody level group (Group H) exhibited a decrease in IgG-H CDR3 diversity after the second vaccination, followed by an increase after the third vaccination. Compared to the extremely low hepatitis B surface antibody level group (Group L), Group H showed higher characteristic immunoglobulin heavy chain variable region V gene ( Conclusion: The prolonged maintenance of ultra-high antibody levels induced by recombinant HBV vaccines in individuals may be closely related to the characteristic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.